Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-02 08:20 am Unchanged | 2025-12-02 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-11-28 09:09 am Unchanged | 2025-11-28 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-11-18 08:25 am Unchanged | 2025-11-18 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-11-10 2:33 pm Unchanged | 2025-11-09 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 26.500% | 0 (Unchanged) | Filing History |
| 2025-11-05 10:31 am Purchase | 2025-11-05 | 13G | Neuphoria Therapeutics Inc. NEUP | Coastlands Capital LP | 120,000 5.100% | 120,000 (New Position) | Filing History |
| 2025-10-31 4:31 pm Purchase | 2025-10-27 | 13G | Neuphoria Therapeutics Inc. NEUP | Baselake Partners, LP | 222,222 9.400% | 222,222 (New Position) | Filing History |
| 2025-10-31 4:00 pm Purchase | 2025-10-24 | 13G | Neuphoria Therapeutics Inc. NEUP | Shay Capital LLC | 171,629 7.300% | 171,629 (New Position) | Filing History |
| 2025-10-23 7:52 pm Purchase | 2025-10-21 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 37.100% | 875,328 (New Position) | Filing History |
| 2025-02-14 5:06 pm Purchase | 2024-12-31 | 13G | Neuphoria Therapeutics Inc. NEUP | Armistice Capital, LLC | 1,033,796 4.990% | 1,033,796 (New Position) | Filing History |
| 2025-01-28 4:30 pm Purchase | 2025-01-24 | 13D | Neuphoria Therapeutics Inc. NEUP | Apeiron Investment Group Ltd. | 72,618 4.500% | 72,618 (New Position) | Filing History |
| 2024-11-14 3:25 pm Purchase | 2024-09-30 | 13G | Bionomics Limited BNOX | Armistice Capital, LLC | 145,462 9.990% | 145,462 (New Position) | Filing History |
| 2024-11-14 09:03 am Sale | 2024-09-30 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 8,245,095 3.200% | -4,119,480 (-33.32%) | Filing History |
| 2024-10-07 6:10 pm Purchase | 2024-10-03 | 13D | Bionomics Limited BNOX | Apeiron Investment Group Ltd. | 23,040,875 8.900% | 23,040,875 (New Position) | Filing History |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | Bionomics Limited BNOX | TANG CAPITAL PARTNERS LP | 0 0.000% | -10,500,000 (Position Closed) | Filing History |
| 2024-02-14 10:20 am Sale | 2023-12-31 | 13G | Bionomics Limited BNOX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -14,174,157 (Position Closed) | Filing History |
| 2024-02-14 09:18 am Sale | 2023-12-31 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 12,364,575 7.800% | -533,400 (-4.14%) | Filing History |
| 2024-02-14 06:45 am Sale | 2023-12-31 | 13G | Bionomics Limited BNOX | Point72 Asset Management, L.P. | 4,965,000 4.000% | -4,959,390 (-49.97%) | Filing History |
| 2023-10-30 4:21 pm Purchase | 2023-09-29 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 12,897,975 8.200% | 12,897,975 (New Position) | Filing History |
| 2023-10-10 4:00 pm Purchase | 2023-09-28 | 13G | Bionomics Limited BNOX | TANG CAPITAL PARTNERS LP | 10,500,000 8.600% | 10,500,000 (New Position) | Filing History |
| 2023-09-29 4:33 pm Purchase | 2023-09-28 | 13G | Bionomics Limited BNOX | Point72 Asset Management, L.P. | 9,924,390 8.100% | 9,924,390 (New Position) | Filing History |